DORIPENEM MONOHYDRATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H24N4O6S2.H2O
Molecular Weight	438.52
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

InChI

InChIKey=NTUBEBXBDGKBTJ-WGLOMNHJSA-N

InChI=1S/C15H24N4O6S2.H2O/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25;/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25);1H2/t6-,7-,8+,9+,10-,11-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C15H24N4O6S2
Molecular Weight	420.504
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4364b1-02-johnson.pdf
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446428/#B1

Doripenem is a synthetic carbapenem that has broad antibacterial potency against aerobic and anaerobic gram-positive and gram-negative bacteria. Doripenem is structurally related to beta-lactam antibiotics and shares the bactericidal mode of action of other β-lactam antibiotics by targeting penicillin-binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall. Doripenem is resistant to hydrolysis by most β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem has many similarities to the other carbapenems, as well as some important differences, such as greater potency against Pseudomonas aeruginosa. It was found to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 232 Target ID: CHEMBL2354204 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Inhibitor 8228		47.6 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Complicated urinary tract infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Curative	Approved 8360	DORIBAX Approved Use Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 1.19724481E12
Nosocomial pneumonia (NP), including ventilator associated pneumonia (VAP). 2 Sources: http://www.sciencedirect.com/science/article/pii/S0924857913000277	Curative	Withdrawn	DORIBAX Approved Use Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 1.19724481E12
Complicated intra-abdominal infections 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Curative	Approved 8360	DORIBAX Approved Use Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 1.19724481E12

C_max

Value	Dose	Analyte	Population
16.87 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.94 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
52.98 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
70.64 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
36.3 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
47.1 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	500 mg 1 times / 8 hour multiple, intravenous dose: 500 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: food status:
66.4 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	1000 mg 1 times / 8 hour multiple, intravenous dose: 1000 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: food status:

T_1/2

Value	Dose	Analyte	Population
2.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.2 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	500 mg 1 times / 8 hour multiple, intravenous dose: 500 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: food status:
2.4 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	1000 mg 1 times / 8 hour multiple, intravenous dose: 1000 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: food status:

F_unbound

Value	Dose	Co-administered	Analyte	Population
91.9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27298719	unhealthy, 24 years (rangeL 21–37 years) n = 16 Health Status: unhealthy Condition: cystic fibrosis Age Group: 24 years (rangeL 21–37 years) Sex: M+F Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/27298719	Disc. AE: Transaminases increased, Allergic reaction... Other AEs: Leukopenia, Diarrhea... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Allergic reaction (1 patient) Other AEs: Leukopenia (1 patient) Diarrhea (11 patient) Nausea (9 patients) Vomiting (9 patients) Headache (6 patients) Oral candidiasis (3 patients) Rash (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/27298719
500 mg 3 times / day steady, intravenous Recommended Dose: 500 mg, 3 times / day Route: intravenous Route: steady Dose: 500 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	unhealthy, 54 years (range: 18-90 years) n = 853 Health Status: unhealthy Condition: intra-abdominal infections Age Group: 54 years (range: 18-90 years) Sex: M+F Population Size: 853 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Disc. AE: Nausea, Vulval mycotic infection... AEs leading to discontinuation/dose reduction: Nausea (0.2%) Vulval mycotic infection (0.1%) Rash (0.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf
5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	unknown, <8 weeks n = 26 Health Status: unknown Age Group: <8 weeks Sex: M+F Population Size: 26 Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	Other AEs: Anemia neonatal, Hypoalbuminemia... Other AEs: Anemia neonatal (3 patients) Hypoalbuminemia (3 patients) Hyperglycemia (2 patients) Peripheral edema (1 patient) Patent ductus arteriosus (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26014957
8 mg/kg single, intravenous Dose: 8 mg/kg Route: intravenous Route: single Dose: 8 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	unknown, >8 weeks <44 weeks n = 26 Health Status: unknown Age Group: >8 weeks <44 weeks Sex: M+F Population Size: 26 Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	Other AEs: Anemia neonatal, Peripheral edema... Other AEs: Anemia neonatal (1 patient) Peripheral edema (1 patient) Dermatitis diaper (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26014957

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1752 inducer 383	inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2A6 704 CYP2B6 799 CYP2C8 901 CYP2C19 1463 CYP2E1 876 CYP3A4/5 273 CYP4A11 21	CYP450 65 P-gp 1527	CYP1A2 689 CYP2B6 538 CYP2C19 290 CYP3A4/5 120 UGT1A1 69

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2A6 736	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2B6 985	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2E1 964	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP3A4/5 330	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP4A11 25	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP1A2 1673	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP2B6 985	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP2C19 1537	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP2C9 1803	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP3A4/5 330	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
UGT1A1 254	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP450 65	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page13 Page: 13.0	no
P-gp 1527	substrate 3326 Sources: https://doi.org/10.1016/j.ijantimicag.2011.11.019 Page: 2.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022106s000_MedR_P8.pdf#page=10 Page: 10.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA006UL2	https://www.aablocks.com/goods/Goods/detail?id=AA006UL2
AHH Chemical co.,ltd	MT-50713	http://www.ahhchemical.com/product/MT-50713.html
Aaron Chemicals	AR006VCU	http://www.aaronchem.com/148016-81-3
Achemo Scientific Limited	AC-66571	http://www.achemo.com/search/?Keyword= 148016-81-3
Achemtek	0104-012333	http://www.achemtek.com/364622-82-2
Active Biopharma	ABP000725	http://www.activebiopharma.com/364622-82-2
Adooq BioScience	A12818	https://www.adooq.com/doripenem.html
Angene	AGN-PC-0Q17TG	http://www.angenechemical.com/productshow/AGN-PC-0Q17TG.html
ApexBio Technology	A2036	http://www.apexbt.com/doripenem-hydrate.html
ApexBio Technology	B1076	http://www.apexbt.com/doripenem.html
Aurora Fine Chemicals LLC	A30.257.818	http://online.aurorafinechemicals.com/info?ID=A30.257.818
AvaChem Scientific	2211	http://www.avachem.com/productSearch.asp?2211
BLD Pharm	BD31996	http://www.bldpharm.com/products/148016-81-3.html
BioCrick	BCC4094	http://www.biocrick.com/Doripenem-BCC4094.html
CSNpharm	CSN16169	https://www.csnpharm.com/products/doripenem.html
Chem Scene	CS-2075	http://www.chemscene.com/148016-81-3.html
ChemMol	49401510	http://www.chemmol.com/chemmol/49401510.html
ChemMol	99046355	http://www.chemmol.com/chemmol/99046355.html
Chemspace	CSSB00000055739	https://chem-space.com/CSSB00000055739
Clearsynth	CS-O-01336	http://www.clearsynth.com/en/CSO01336.html
Glentham Life Sciences	GA9212	http://www.glentham.com/products/product/GA9212/
Hefei Hirisun Pharmatech Co., Ltd	HR131453	http://hirisunpharm.com/148016-81-3.html
Lab Network	LN01314809	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01314809
Matrix Scientific	146744	https://www.matrixscientific.com/146744.html
MedChem Express	HY-B0187	https://www.medchemexpress.com/doripenem.html
MuseChem	I001815	https://www.musechem.com/product/I001815.html
OChem	7587	http://www.ocheminc.com/index.php?act=psearch&pid=016D813
Parchem	28774	http://www.parchem.com/chemical-supplier-distributor/Doripenem-018774.aspx
Renno Tech	RL01870	http://www.rennotech.com/product_show.asp?id=2119
Selleck Chemicals	S5531	http://www.selleckchem.com/products/doripenem.html
Smolecule	S560427	https://www.smolecule.com/products/s560427
TCI (Tokyo Chemical Industry)	D5249	http://www.tcichemicals.com/eshop/en/us/commodity/D5249/index.html
THE BioTek	bt-288875	https://www.thebiotek.com/product/others/bt-288875
abcr GmbH	AB452160	http://www.abcr.com/shop/en/AB452160
eNovation Chemicals	D320169	http://www.enovationchem.com/productDetails.asp?productID=D320169
iChemical	EBD29332	http://www.ichemical.com/products/148016-81-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed

Comparative review of the carbapenems.	2007	17488146
Empiric treatment options in the management of complicated intra-abdominal infections.	2007 Aug	17847176
[Antimicrobial activity of meropenem against main bacterial species isolated from patient blood in 2006].	2007 Dec	18447207
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.	2007 Dec	17997070
Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients.	2007 Dec	17884833
Carbapenems in the USA: focus on doripenem.	2007 Oct	17914914
Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.	2008	18983709
Doripenem: a review of its use in the treatment of bacterial infections.	2008	18778123
"The truth, if it exists, is in the details".	2008 Apr	18379272
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.	2008 Apr	18379232
Current therapies for pseudomonas aeruginosa.	2008 Apr	18361945
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.	2008 Apr	17705288
Gateways to clinical trials. December 2008.	2008 Dec	19271026
New developments in carbapenems.	2008 Dec	19076841
What's new and not so new on the antimicrobial horizon?	2008 Dec	19040463
[In-vitro activity of panipenem against clinical isolates in 2006].	2008 Feb	18536215
Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.	2008 Feb	18246520
Carbapenems: a potent class of antibiotics.	2008 Jan	18076336
Doripenem (Doribax)--a new parenteral carbapenem.	2008 Jan 28	18219262
New drugs: doripenem, raltegravir, and ixabepilone.	2008 Jan-Feb	18192140
Doripenem: a new carbapenem.	2008 Jul	18717294
Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation.	2008 Jun	18574662
The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.	2008 Mar	18312158
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x.	2008 Mar	18238882
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.	2008 May	18555934
Doripenem (doribax)--a new parenteral carbapenem.	2008 May	18448759
Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection.	2008 May 1	18356120
Current status of newer antiinfectives.	2008 Nov	18991803
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.	2008 Nov	18819979
New antibiotic agents for bloodstream infections.	2008 Nov	18723329
Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.	2008 Nov	18703305
Lucasti et al in the May 2008 issue of Clinical Therapeutics.	2008 Oct	19014850
Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model.	2008 Sep	18314887
Current treatment of pseudomonal infections in the elderly.	2009	19552489
Current status of newer carbapenems.	2009	19199922
Doripenem: antimicrobial profile and clinical potential.	2009 Apr	19302929
Activity of a novel carbapenem, doripenem, against anaerobic pathogens.	2009 Apr	19249176
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.	2009 Apr	19249175
Update on the treatment of Pseudomonas aeruginosa pneumonia.	2009 Aug	19520717
Doripenem-induced intertriginous drug eruption as a mild form of AGEP.	2009 Aug	19453777
Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.	2009 Aug	19394788
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.	2009 Feb	18977642
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.	2009 Jul	19553404
Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.	2009 Jul	19398458
Doripenem.	2009 Jul 15	19527173
Doripenem: position in clinical practice.	2009 Jun	19485791
Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.	2009 Jun	19369268
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.	2009 Mar	19155227
Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.	2009 Mar	19095418

Patents

Sample Use Guides

In Vivo Use Guide

500 mg administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age; for complicated intra-abdominal infection 5–14 days, for complicated UTI, including pyelonephritis 10 days.

Route of Administration: Intravenous

In Vitro Use Guide

HardyDisk™ Doripenem Antimicrobial Susceptibility Test Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. The concentration of doripenem 10ug has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus constellatus, Streptococcus intermedius

Substance Class	Chemical Created by `admin` on `Thu Jul 06 02:50:31 UTC 2023` Edited by `admin` on `Thu Jul 06 02:50:31 UTC 2023`
Record UNII	4B035T6NKT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DORIPENEM MONOHYDRATE

Common Name

English

DRIPENEM HYDRATE

Common Name

English

FINIBAX

Common Name

English

DORIPENEM HYDRATE [MI]

Common Name

English

DORIPENEM HYDRATE

Common Name

English

Doripenem monohydrate [WHO-DD]

Common Name

English

DORIPENEM HYDRATE [JAN]

Common Name

English

(4R,5.BETA.)-3-(((3S)-5.BETA.-((SULFAMOYLAMINO)METHYL)PYRROLIDINE-3.BETA.-YL)THIO)-4.ALPHA.-METHYL-6.BETA.-((1R)-1-HYDROXYETHYL)-7-OXO-1-AZABICYCLO(3.2.0)HEPTA-2-ENE-2-CARBOXYLIC ACID HYDRATE

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

DORIBAX (WITHDRAWN: PNEUMONIA, VENTILATOR-ASSOCIATED)